Rayner completes pivotal dropless cataract surgery study with OMIDRIA®
Posted on 25/03/2025
In a major step toward redefining postoperative care and elevating patient experience, Rayner – a global leader in cataract surgery products – proudly announces the successful completion of its pivotal U.S. dropless cataract surgery study.
OMIDRIA (phenylephrine and ketorolac intraocular solution 1% / 0.3%) is the only FDA-approved NSAID for use during cataract surgery, indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative pain. The interim results of this study of 188 eyes found no statistically significant difference in inflammation or mean retinal thickness between the dropless regimen including OMIDRIA, subconjunctival triamcinolone, and intracameral moxifloxacin and standard topical drops on days 1, 8 and 30. Notably, an overwhelming 90% of patients preferred the OMIDRIA regimen compared to 42% for standard eye drops.
Interim study results were presented at the American Academy of Ophthalmology meeting in Chicago by Drs. Cathleen McCabe, Paul Singh, and Brian Shafer, setting the stage for a significant advancement in the recovery process for cataract surgery patients.
Dr. Cathleen McCabe, The Eye Associates, FL shared “These findings reinforce OMIDRIA as the cornerstone of dropless cataract surgery regimens, delivering the only FDA-approved intracameral NSAID to minimize postoperative complications by controlling inflammation directly at the site of care.”
Dr. I Paul Singh, Eye Center of Racine and Kenosha, WI stated “Patients loved the convenience of a dropless regimen. This study supports a patient-preferred approach, and I now offer dropless cataract surgery to more of my patients.”
Dr. Brian Shafer, Shafer Vision Institute, PA emphasized What surprised me was the impact it had on our clinic efficiency and flow, allowing staff to focus on more productive tasks.” Dropless regimens have been shown to save over 3000 staff hours annually.1
The study’s completion delivers a full 90-day data set, solidifying OMIDRIA’s role as a game changer in dropless cataract surgery. The full dataset will be presented at the American Society of Cataract and Refractive Surgery in Los Angeles. Register for Rayner’s breakfast symposium here.
Discover the potential of a dropless future with OMIDRIA: access educational resources and clinical insights at www.omidria.com and youtube.com/Rayner.global.
- Lindstrom RL, Galloway MS, Grzybowski A, Liegner JT. Dropless cataract surgery: an overview. Curr Pharm Des. 2017;23(4):558–564.
About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley in 1949, Rayner has the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Rayner markets its medical devices, pharmaceuticals, and digital solutions globally through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
Portions of the information included in this press release is based on interim data and is provided for informational purposes only. The results and conclusions presented herein are subject to change as further analysis and validation are conducted. These findings have not yet been peer-reviewed or confirmed through additional studies, and therefore, should not be interpreted as definitive or conclusive.
Readers are cautioned not to place undue reliance on the interim data, which may differ from final results or outcomes.
This is a studied postoperative cataract surgery regimen that may not be for everyone. Rayner does not recommend any specific combination use of products.
Rayner, the Rayner logo and OMIDRIA are proprietary marks of Rayner. ©2025 Rayner Group, all rights reserved. US-OM-2500xx 03/25